We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

The high cost of recycling

14 Jul 2005 By Robert Cyran

The Swiss pharma s strategy of recycling cash from patented drugs into lowmargin generic treatments is proving costly, as Q2 figures show. Other pharma companies have dropped this strategy. Novartis should too.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)